Selleck Chemicals - Model A2515 -Parsatuzumab (Anti-EGFL7)

Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD.